Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic TM Antisense ...

US-based Normunity has raised $75m in a Series B funding round to support the clinical development of its lead programme, NRM-823, a potential first-in-class T-cell engager (TCE) targeting solid ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Following the announcement, the firm removed clinical program revenue from its model and lowered its view of platform value to $50M, mostly related to the still-ongoing Sanofi (SNY) partnership ...

Nagpur: Saoner MLA Ashish Deshmukh has unveiled comprehensive plans for Saoner-Kalmeshwar area, encompassing an integrated fertiliser complex and a ferro alloy plant, aimed at fostering industrial ...

Identifying alloy properties can be expensive and time-consuming. Experiments involving alloys often require a number of resources. Calculating alloys can also become extremely complicated ...

We are at a critical time and supporting climate journalism is more important than ever. Science News and our parent organization, the Society for Science, need your help to strengthen ...

Sanofi (NASDAQ:SNY) said that a Phase 3 study of its new subcutaneous formulation of Sarclisa in the treatment of multiple myeloma met its co-primary endpoints, demonstrating non-inferiority to ...

[Read: Science is becoming less human] “The big turning point in the space was six years ago,” Ziv Bar-Joseph, a computational biologist at Carnegie Mellon University and the head of research and ...

In Jan 2025, Alloy announced a target specific collaboration and license agreement for the use of their Platform with Sanofi for a central nervous system (CNS) target. In return, Sanofi will provide ...